Abstract Proteasome inhibitor Bortezomib/Velcade has emerged as an effective anticancer
therapy for the treatment of relapsed and/or refractory multiple myeloma (MM), but prolonged …

Proteasome inhibition represents a new anticancer approach, with the potential effect of
arresting tumor growth, metastasis and angiogenesis through the activation of multiple …

Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated
for single-agent use in the treatment of patients with multiple myeloma who have received at …

The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular
proteins, including cell cycle regulatory proteins. Because these pathways are critical for the …

Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …

Bortezomib (VELCADE®) is a proteasome inhibitor that not only targets the myeloma cell,
but also acts in the bone marrow micro-environment, inhibiting the binding of myeloma cells …

Cellular homeostasis requires routine degradation of key regulatory proteins, including
tumor suppressor gene products, transcription factors, cell-cycle proteins and their inhibitors …

Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its
microenvironment, resulting in down-regulation of growth and survival signaling pathways …

Bortezomib therapy has proven successful for the treatment of relapsed, relapsed/refractory,
and newly diagnosed multiple myeloma (MM). At present, bortezomib is available as an …

The proteasome is responsible for the degradation of intracellular proteins, including several
involved in cell cycle control and the regulation of apoptosis. Preclinical studies have shown …